Fredrik Jarskog, MD. Associate Professor of Clinical Psychiatry, Chief of Clinical Therapeutics Lieber Center for Schizophrenia Research and Treatment New York State Psychiatric Institute/Columbia University.

Dr. Jarskog has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity. Dr. Jarskog has disclosed that glycine, D-serine, D-cycloserine, and Glu2/3 receptor agonists are not FDA-approved for the treatment of schizophrenia.